Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Antihero
|
| gptkbp:administered_by |
oral tablet
|
| gptkbp:approves |
gptkb:2011
gptkb:FDA |
| gptkbp:available_on |
generic drug
|
| gptkbp:brand |
gptkb:Xarelto
|
| gptkbp:chemical_formula |
C19 H18 Cl N3 O5 S
|
| gptkbp:clinical_trial |
Phase IV
Phase III |
| gptkbp:clinical_use |
long-term therapy
short-term therapy |
| gptkbp:contraindication |
active bleeding
severe renal impairment |
| gptkbp:developed_by |
gptkb:Johnson_&_Johnson
gptkb:Bayer_AG |
| gptkbp:dosage_form |
gptkb:tablet
10 mg 15 mg 20 mg |
| gptkbp:formulation |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
rivaroxaban
|
| gptkbp:initiated_by |
gptkb:Andexanet_alfa
Prothrombin complex concentrate |
| gptkbp:interacts_with |
NSAIDs
antiplatelet agents other anticoagulants |
| gptkbp:invention |
2024
|
| gptkbp:is_monitored_by |
renal function
liver function |
| gptkbp:lifespan |
5 to 9 hours
|
| gptkbp:marketed_as |
over 100 countries
|
| gptkbp:mechanism_of_action |
factor Xa inhibitor
|
| gptkbp:patient_population |
adults
elderly patients with DVT patients with PE patients with atrial fibrillation |
| gptkbp:research_areas |
cardiology
hematology thrombosis |
| gptkbp:rounds |
urine
feces |
| gptkbp:side_effect |
nausea
bleeding liver enzyme elevation |
| gptkbp:storage |
room temperature
protected from moisture |
| gptkbp:suitable_for |
pregnancy
lactation |
| gptkbp:used_for |
preventing blood clots
treating deep vein thrombosis treating pulmonary embolism preventing stroke in atrial fibrillation |
| gptkbp:weight |
435.87 g/mol
|
| gptkbp:bfsParent |
gptkb:Xarelto
|
| gptkbp:bfsLayer |
5
|